Reasons | Group L, n (%) | Group D, n (%) | P valuea |
---|---|---|---|
Continuation for clinical success | 17 (44%) | 30 (70%) | 0.025 |
Clinical failure or not evaluable | 3 (8%) | 3 (7%) | 1.000 |
Adverse event | 12 (31%) | 3 (7%) | 0.009 |
Shift to another antibiotic after identification or for no efficacy | 3 (8%) | 6 (14%) | 0.487 |
Fixed administration duration in advance | 2 (5%) | 1 (2%) | 0.602 |
Unknown | 2 (5%) | 0 (0%) | 0.223 |